Clinical trial • Phase III • Endocrinology
cagrilintide and semaglutide for Obesity
Phase III trial of cagrilintide and semaglutide for Obesity. 100 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Obesity
- Trial Stage
- Phase III
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 05-12-2025
- First CTIS Authorization Date
- 06-03-2026
Trial design
Phase III trial across 1 site in Denmark.
- Target Sample Size
- 100
- Trial Duration For Participant
- 791
Recruitment
- Planned Sample Size
- 100
- Recruitment Window Months
- 26
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 100
Denmark
- Earliest CTIS Part Ii Submission Date
- 30-01-2026
- Latest Decision Or Authorization Date
- 06-03-2026
- Processing Time Days
- 35
- Number Of Sites
- 1
- Number Of Participants
- 100
Sites
- Site Name
- Region Midtjylland
- Department Name
- Aarhus Universitetshospital, Steno Diabetes Center Aarhus
- Principal Investigator Name
- Niels Jessen
- Principal Investigator Email
- niels.jessen@biomed.au.dk
- Contact Person Name
- Niels Jessen
- Contact Person Email
- niels.jessen@biomed.au.dk
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- CagriSema
- Active Substance
- cagrilintide and semaglutide
- Modality
- Peptide/protein/enzyme
- Investigational Product Name
- cagrilintide
- Active Substance
- cagrilintide
- Modality
- Peptide/protein/enzyme
- Investigational Product Name
- semaglutide
- Active Substance
- semaglutide
- Modality
- Peptide/protein/enzyme
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- TIRZEPATIDE for Obesity
- RO7795068 for Obesity
- L-PHENYLALANYL-2-METHYLALANYL-L-ALFA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALFA-ASPARTYL-L-VALYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-LEUCYL-L-ALFA-GLUTAMYL-L-ALFA-GLUTAMYL-L-LYSYL-L-ARGINYL-L-VALYL-L-ARGINYL-L-ALFA-GLUTAMYL-L-PHENYLALANYL-L-ISOLEUCYL-L-ALFA-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-GLUTAMINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-PROLYL-L-PROLYLGLYCYL-L-LYSYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL]-L-LYSINE for Obesity
- cagrilintide for Obesity
- ZENAGAMTIDE for Obesity